Effects of high-dose imatinib alone or in combination with peginterferon alfa-2b in patients with chronic myeloid leukaemia in early chronic phase.

Trial Profile

Effects of high-dose imatinib alone or in combination with peginterferon alfa-2b in patients with chronic myeloid leukaemia in early chronic phase.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2011

At a glance

  • Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Imatinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top